Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial by Pignata, Sandro, MD, Lorusso, Domenica, MD, Joly, Florence, MD, Gallo, Ciro, Prof, Colombo, Nicoletta, Prof, Sessa, Cristiana, Prof, Bamias, Aristotelis, Prof, Salutari, Vanda, MD, Selle, Frédèric, MD, Frezzini, Simona, MD, De Giorgi, Ugo, MD, Pautier, Patricia, MD, Bologna, Alessandra, MD, Orditura, Michele, Prof, Dubot, Coraline, MD, Gadducci, Angiolo, Prof, Mammoliti, Serafina, MD, Ray-Coquard, Isabelle, Prof, Zafarana, Elena, MD, Breda, Enrico, MD, Favier, Laure, MD, Ardizzoia, Antonio, MD, Cinieri, Saverio, Prof, Largillier, Rémy, MD, Sambataro, Daniela, MD, Guardiola, Emmanuel, MD, Lauria, Rossella, MD, Pisano, Carmela, MD, Raspagliesi, Francesco, MD, Scambia, Giovanni, MD, Daniele, Gennaro, MD, Perrone, Francesco, MD

Get full text